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ACQUIRED CARDIOVASCULAR DISEASE: CORONARYPercutaneous coronary invervention versus coronary artery bypass
grafting: A meta-analysisYolba Smit, MD, MSc,a Joan Vlayen, MD,b Hetty Koppenaal, MD, MPH,c Frank Eefting, MD,d
Arie Pieter Kappetein, MD, PhD,e and Massimo A. Mariani, MD, PhDfA
C
DABSTRACT
Objective: To compare the effectiveness of percutaneous coronary intervention
(PCI) and coronary artery bypass grafting (CABG) in patients with coronary ar-
tery disease.
Methods: MEDLINE, Embase, and Cochrane Central were searched, and ran-
domized controlled trials were included. Outcomes were assessed at maximum
available follow-up.
Results: This meta-analysis includes 31 trials with 15,004 patients. As regards
death, more patients died after PCI compared with CABG across all types of pa-
tients (odds ratio [OR], 1.1; 95% confidence interval [CI], 1.0-1.3; P ¼ .05) as
well as in patients with multivessel disease (OR, 1.2; 95% CI, 1.0-1.4; P ¼ .02)
or diabetes (OR, 1.6; 95% CI, 1.2-2.1; P<.01). Myocardial infarction occurred
as frequently after PCI (OR, 1.2; 95%CI, 0.9-1.5; P¼ .28). Repeat revasculariza-
tion was more common after PCI (OR, 4.5; 95% CI, 3.5-5.8; P<.01), with a pro-
gressive decline in ORs from the pre-stent era (OR, 7.0; 95%CI, 5.1-9.7; P<.01),
to the bare metal stent era (OR, 4.5; 95% CI, 3.6-5.5; P<.01), and to the drug-
eluting stent era (OR, 2.5; 95% CI, 1.8-3.4; P<.01). Stroke was more common
after CABG (OR, 0.7; 95% CI, 0.5-0.9; P ¼ .01).
Conclusions: Compared with PCI, CABG had a lower risk of death in multivessel
disease or diabetes patients eligible for either intervention, a lower risk of
repeat revascularization, but a higher risk of stroke. (J Thorac Cardiovasc Surg
2015;149:831-8)From Independent Researcher,a Leuth, The Netherlands; ME-TA,b Rotselaar,
Belgium; Independent Researcher,c Vlissingen, The Netherlands; Department of
Cardiology,d St Antonius Hospital, Nieuwegein, The Netherlands; Department of
Cardiothoracic Surgery,e ErasmusMedisch Centrum, Rotterdam, The Netherlands;
and Department of Cardiothoracic Surgery,f UniversityMedical Centre Groningen,
University of Groningen, Groningen, The Netherlands.
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We conducted a meta-analysis comparing the effectiveness
of PCI to CABG in 31 trials on 15,004 patients. Compared
to PCI, CABG had a lower risk of death in patients withmul-
tivessel disease or diabetes, and a lower risk of repeat revas-
cularization and a higher risk of stroke in all patients.Author Perspective
This paper supports current thoughts in myocardial revascu-
larization directed to reconsider the role of surgical myocar-
dial revascularization in patients with extensive coronary
artery disease, particularly when affected by diabetes. On
the other hand, this paper confirms that additional effort
should be put in lowering the risk of perioperative neurologic
complications in surgical myocardial revascularization
because stroke is a rare but devastating and invalidating
complication. Off-pump and aortic ‘‘no-touch’’ techniques
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Revascularization for coronary artery disease can be
performed with coronary artery bypass grafting (CABG)
or percutaneous coronary intervention (PCI). For more
than 20 years, trials have compared the effectiveness and
safety of PCI versus CABG. The first trials compared
balloon angioplasty to CABG. Improved technology has
made it possible to treat increasingly complex lesionswith PCI. At the same time, the outcome of CABG has
improved because of better perioperative care and extended
use of arterial revascularization. After the introduction of
bare metal stents, several trials compared PCI with CABG
in patients with multivessel disease. More recently, data
from randomized trials of drug-eluting stents have shown
significant reductions in the rate of repeat interventions
with respect to bare metal stents. The latest trials therefore
focused on PCI with drug-eluting stents versus CABG.
Earlier meta-analyses of randomized controlled trials
(RCTs) comparing PCI versus CABG have been undertakenril 23, 2014; revisions received Oct 17, 2014; accepted
14; available ahead of print Nov 25, 2014.
o A. Mariani, MD, PhD, Department of Cardiothoracic
al Center Groningen, University of Groningen, P.O. Box
en, The Netherlands (E-mail: m.mariani@umcg.nl).
merican Association for Thoracic Surgery
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Abbreviations and Acronyms
AMIST ¼ Angioplasty versus Minimally
Invasive Surgery Trial
ARTS ¼ Arterial Revascularization
Therapies Study
AWESOME ¼ Angina With Extremely Serious
Operative Mortality Evaluation
BARI ¼ Bypass Angioplasty
Revascularization Investigation
CABG ¼ coronary artery bypass grafting
CABRI ¼ Coronary Angioplasty versus
Bypass Revascularisation
Investigation
CAD ¼ coronary artery disease
CARDia ¼ Coronary Artery
Revascularization in Diabetes
CI ¼ confidence interval
EAST ¼ Emory Angioplasty versus
Surgery Trial
EXCEL ¼ Coronary Artery Bypass Surgery
for Effectiveness of Left Main
Revascularization
ERACI I ¼ Argentine Randomized Trial of
Percutaneous Transluminal
Coronary Angioplasty Versus
Coronary Artery Bypass Surgery
in Multivessel Disease
ERACI II ¼ Argentine Randomized Trial of
Coronary Angioplasty With
Stenting Versus Coronary Bypass
Surgery in Patients with Multiple
Vessel Disease trial
FREEDOM ¼ Future REvascularization
Evaluation in patients with Diabetes
mellitus: Optimal management of
Multivessel disease
GABI ¼ German Angioplasty Bypass
Surgery Investigation
LAD ¼ left anterior descending coronary
artery
LMCA ¼ left main coronary artery
MASS ¼Medicine, Angioplasty, or Surgery
Study
OR ¼ odds ratio
PCI ¼ percutaneous coronary
intervention
PRECOMBAT ¼ Premier of Randomized
Comparison of Bypass Surgery
versus Angioplasty Using
Sirolimus-Eluting Stent in
Patients with Left Main Coronary
Artery Disease
RCT ¼ randomized controlled trial
RITA ¼ Randomised Intervention
Treatment of Angina
SIMA ¼ Stenting versus Internal Mammary
Artery grafting trial
SYNTAX ¼ Synergy Between Percutaneous
Coronary Intervention With Taxus
and Cardiac Surgery
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Dwith the purpose of evaluating both treatment modalities.
These meta-analyses either are now outdatedE1-E3 or
present only part of the picture, as they looked at
particular disease categories,E4-E10 specific types of
surgery or PCI,E1,E7,E11 or specific patients.E12 Individual
patient data meta-analyses have the advantage that
time-to-event curves can be produced, and analyses of
effects in clinically important subgroups can be estimated.
However, they are limited by the willingness and/or ability
of research groups to participate and share data.E13-E15
The present meta-analysis aims to compare the effective-
ness and safety of PCI and CABG in patients for whom
coronary revascularization is clinically indicated.
METHODS
Search Strategies
WeusedCochrane systematic reviewmethods to identifyRCTs thatmet the
inclusion criteria. MEDLINE, Embase, and Cochrane Central were searched
on December 18, 2013, using text words and medical subheadings. Searches
were limited to studies published from 1996 onwards, published in English,
and undertaken in humans.Because of continuous improvement of techniques,
devices, andmedical treatment, studiespublishedbefore1996were considered
too old to have policy implications for current clinical practice. References of
meta-analyses, reviews, and selected articles were scanned for additional
RCTs. The websites www.controlled-trials.com and clinicaltrial.gov were
searched for running and unpublished trials, and when such trials were found,
the Internet was searched for preliminary or early results. Two databases
(Database of Abstracts of Reviews of Effects and the Health Technology
Assessment database) were searched via http://www.crd.york.ac.uk/crdweb/.
Inclusion Criteria
Studies were included if they concerned an RCT comparing PCI (with or
without stenting) toCABGand if the trial participantswere adults with stable
or unstable angina, and had single-vessel or multivessel coronary disease.
Study Selection and Quality Criteria
Two reviewers (YS and HK or JV) independently selected the studies;
discrepancies were resolved by consensus. Selected trials were assessed
for their methodological quality (adequacy of randomization, adequacy
of the allocation concealment, the potential for selection bias after
allocation and the adequacy of masking) by 2 reviewers (YS and HK or
JV) using a scheme based on Schulz et al, which was used in Cochrane
reviews on CABG and PCI.E1,E16,E17
Data Extraction
Datawere extractedby one reviewer (YS) and checked by a second (HKor
JV). Events of interest included the primary outcome measures (all-cause
death,myocardial infarction, repeat revascularization, and stroke), secondary
outcome measures (cardiac death and angina-free survival), general charac-
teristics of the included studies, and data on study participants (eg, type ofery c March 2015
Smit et al Acquired Cardiovascular Disease: Coronaryvessel involvement). For outcomes, the numerator was the number of events
reported; the denominator was the number of patients assigned to a treatment
arm (intention-to-treat principle). For myocardial infarction, the number of
nonfatal infarctions was taken and, when not available, the number of
nonfatal Q-wave infarctions, myocardial infarctions, or myocardial Q-wave
infarctionswas taken (in that order). For repeat revascularization, the number
of procedures was taken and, when not available, the number of patients with
a repeat revascularization was taken. When the number of repeat revascular-
izations was not available, the number of repeat target vessel revasculariza-
tions was taken. For angina-free survival, either the number of patients
reported to be angina-free was taken or the number of patients with angina
was subtracted from the total number of patients minus the dead. For stroke,
the number of patients with a nonfatal stroke at follow-up was taken. If not
available, the number of patientswith a strokewas taken. Datawere extracted
separately for all reported time points of follow-up (eg, at 1, 2, and 5 years of
follow-up), and for the clinical significant subgroup of patients with diabetes.A
C
DData Analysis
Medians were calculated as the middle number in a list of ordered
numbers, as a summary statistic for the proportion of screened patients
(patients assessed for eligibility) that were included in trials, the proportion
of patients lost to follow-up, and the proportion of off-pumpCABG in trials
that used a mix of on-pump and off-pump techniques. Meta-analyzed
outcomes were assessed at maximum available follow-up, unless otherwise
specified. Outcomes were presented as odds ratios (ORs) with the
corresponding 95% confidence intervals (CIs). A P value of .05 or smaller
was considered statistically significant. A continuity correction of 0.5 was
applied in case of zero events in 1 treatment arm. Meta-analyzed results
were described using a random effects model. Heterogeneity was assessed
with the c2 Q statistic, and the I2 metric with its 95% CIs.E18 Values of I2
75% suggest very large heterogeneity beyond chance, in which case
meta-regression (method of moments) was applied to explore reasons for
heterogeneity. Outcomes were also meta-analyzed according to the type
of PCI that was evaluated: the pre-stent era (no stents used in the majority
of patients, up to 1993); the bare metal stent era (bare metal stents used in
the majority of patients, 1994-2001); and the drug-eluting stent era
(drug-eluting stents used in the majority of patients, from 2002 onwards).
We performed sensitivity analyses excluding studies in which a substantial
minority (10% or more) of patients received a different type of PCI, for
example, in a trial in the bare metal stent era 90% of patients were treated
with bare metal stents and 10% of patients were treated with drug-eluting
stents. Although CABG has evolved as well across these time periods—
with a greater use of arterial conduits, off-pump surgery, and minimally
invasive surgical techniques—this evolvement is not captured as
unequivocal in different eras. In addition, meta-analysis of outcomes at
time periods of 6 months, 1 year, 1.5 to 2 years, 2.5 to 3 years, 4 years,
and 5 years of follow-up was performed for the primary outcomes.
Meta-analyses of primary outcomes were performed separately for trials
reporting on different types of vessel disease and for trials using either
off-pump or on-pump CABG exclusively. For the subgroup analyses of
off-pump versus on-pump CABG, we excluded trials from the pre-stent
era, as none of these trials used off-pumpCABG. In addition, we performed
meta-analyses of primary outcomes for diabetes patients (either trials that
exclusively included patients with diabetes or trials that reported on sub-
groups of patients with diabetes). Funnel plots were constructed and the
Duval and Tweedie’s trim and fill test was applied to examine
publication bias. We undertook sensitivity analyses of subgroups with
different quality assessment scores. Analyses were performed using
Comprehensive Meta-Analysis software, version 2.0 (Biostat, Englewood,
NJ). Stata, version 10.0 (StataCorp, College Station, Tex) was used to
calculate 95% CI for frequencies not provided in original publications
and the 95% CI of I2.E19 Microsoft Office Excel 2007 was used for graphs
picturing meta-analyzed ORs per time period of follow-up. The ORs given
are always for PCI versus CABG.The Journal of Thoracic and CaRole of the Funding Source
The sponsor of the study had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.
RESULTS
A total of 4837 records were screened out of which 302 ar-
ticles were selected for full text review. From these 302 arti-
cles, 31 RCTs were selected for inclusion, and data from 91
articles pertaining to these trials were used in the meta-ana-
lyses.E20-E110 If multiple articles were available on a single
study, we would only use the most recent or most
comprehensive article, unless data for different time periods
of follow-up or for different subgroups of patients were not
reported in these articles. A flow diagram in Appendix E1
shows the search and selection process. The Angina With
Extremely Serious Operative Mortality Evaluation
(AWESOME) trial was excluded because patientswithmedi-
cally refractory unstable ischemia and a high risk of adverse
outcomes were involved,E111-E117 whereas the 31 selected
RCTs had strict exclusion criteria for patients with a recent
myocardial infarction, a previous PCI or CABG, low left
ventricular ejection fraction, or serious comorbidity.
Characteristics
The 31 RCTs included a total of 15,004 randomized
patients (Table 1). One more trial of drug-eluting stents
versus CABG is running at present, the Coronary Artery
Bypass Surgery for Effectiveness of Left Main Revascular-
ization (EXCEL) trial, but its results have not been published
to date.E118 Nine trials (5200 patients) were conducted in the
pre-stent era, 14 trials (4276 patients) in the bare metal stent
era, and 8 trials (5528 patients) in the drug-eluting stent era.
Mixed PCI treatments did not occur in the pre-stent era.
However, in 5 out of 14 trials conducted in the bare metal
stent era, more than 10% of patients randomized to PCI
were treated with either angioplasty alone (13% of patients
randomized to PCI in the Arterial Revascularization Thera-
pies Study [ARTS] trial, 30% in the Argentine Randomized
Trial of Coronary Angioplasty With Stenting Versus Coro-
nary Bypass Surgery in Patients with Multiple Vessel Dis-
ease [ERACI II] trial, 28% in the Medicine, Angioplasty,
or Surgery Study [MASS] II trial, and 22% in the Stent or
Surgery [SoS] trial) or with drug-eluting stents (35% of
patients randomized to PCI in the le Mans trial). In the
Coronary Artery Revascularization in Diabetes (CARDia)
trial, 31% of patients randomized to PCI were treated with
baremetal stents and 69%with drug-eluting stents (this trial
was categorized in the drug-eluting stent era). PCI and
CABG were compared in patients with multivessel disease
(n ¼ 12), proximal left anterior descending coronary artery
(LAD) stenosis (n ¼ 11), patients with main stem stenosis
(n¼ 4), a combination of patients with single- ormultivessel
disease (n¼ 2), or 3-vessel or left main coronary artery ste-
nosis (n¼ 2). Trials included a median of 7.8% of screened
patients (range, 2.0%-61%). Follow-up was available fromrdiovascular Surgery c Volume 149, Number 3 833
TABLE 1. Characteristics of 31 PCI versus CABG trials, per treatment era
Trial name



























BARIE20-E28 Multicenter, United States
and Canada
1988-1991 1829 7.3 2.8 10 Multivessel CAD 0 Yes
CABRIE29-E32 Multicenter, Europe 1988-1992 1054 na 0.4 4 Multivessel CAD 0y Yes
EASTE33-E36 Single-center, United States 1987-1990 392 7.7 0 8 Multivessel CAD 0 Yes
ERACI IE37,E38 Single-center, Argentina 1988-1990 127 17.0 1.6 3 Multivessel CAD 0 No
French Monocentric
StudyE39
Single-center, France 1989-1993 152 7.8 na 5 Multivessel CAD 0 No
GABIE40,E41 Multicenter, Germany 1986-1991 359 4.0 0.5 13 Multivessel CAD 0 No
Goy et alE42,E43z Single-center, Switzerland 1989-1993 134 2.6 na 5 Proximal LAD stenosis 0 No
MASS IE44,E45 Single-center, Brazil 1988-1991 142 na na 5 Proximal LAD stenosis 0 No
RITA IE46-E50 Multicenter, United Kingdom 1988-1991 1011 4.4 0 6.5 Single- or multivessel
CAD
0y Yes
Bare metal stent era 4276
AMISTE51x Multicenter, United Kingdom 1999-2001 100 9.2 8.0 1.5 Proximal LAD stenosis 100 No
ARTSE52-E59k Multicenter, international 1997-1998 1205 na 1.7 5 Multivessel CAD 0 Yes
Cisowski et alE60,E61 Single-center, Poland 2000-2001 100 na 0 2 Proximal LAD stenosis 100 No
Diegeler et alE62-E64 Single-center, Germany 1997-2001 220 na 3.6 10 Proximal LAD stenosis 100 No
Drenth et alE65-E68 Single-center, The Netherlands 1997-1999 102 na 0 4 Proximal LAD stenosis 100 No
ERACI IIE69,E70{ Multicenter, Argentina 1996-1998 450 16.3 0 5 Multivessel CAD 0y Yes
Grip et alE71 Single-center, Sweden 2001 53 na 0 0.5 Proximal LAD stenosis 100 No
Kim et alE72 Single-center, South Korea 2000-2001 100 na na 1 Proximal LAD stenosis 100 No
Le MansE73,E74# Multicenter, Poland 2001-2004 105 30.3 0 10 Main stem stenosis 0 No
MASS IIE75-E80** Single-center, Brazil 1995-2000 408 2.0 0 10 Multivessel CAD 0 Yes
MyoprotectE81 Single-center, Germany 1998-2001 44 na na 1 Main stem stenosisyy 19 No
OctostentE82-E84 Multicenter, The Netherlands 1998-2000 280 na na 7.5 Single- or multivessel
CAD
100 No
SIMAE85,E86 Multicenter, Europe 1994-1998 121 na 0 10 Proximal LAD stenosis 10 No
SoSE87-E90zz Multicenter, Canada and
Europe
1996-1999 988 na 0.8 6 Multivessel CAD 3 Yes
Drug-eluting stent era 5528
Boudriot et alE91,E92 Multicenter, Germany 2003-2009 201 46.7 0.5 5 Main stem stenosis 46 No
CARDiaE93xx Multicenter, United Kingdom
and Ireland
2002-2007 510 na 3.9 1 Diabetes patients with
multivessel CAD
31 Yes
FREEDOME94-E96 Multicenter, international 2005-2010 1900 5.8 1 5 Diabetes patients with
multivessel CAD
18.5 Yes
Hong et alE97 Single-center, South Korea 2003 189 na 0.8 0.5 Proximal LAD stenosis 100 No
PRECOMBATE98 Multicenter, South Korea 2004-2009 600 41.3 0 2 Main stem stenosis 64 No
SYNTAXE99-E108 Multicenter, international 2005-2007 1800 41.5 0.7 5 3-vessel or LMCA
stenosis
15 Yes
Thiele et alE109kk Single-center, Germany 2003-2007 130 61.0 0 1 Proximal LAD stenosis 100 No
Veterans AffairsE110 Multicenter, United States 2006-2010 198 3 na 2 Diabetes patients with
severe CAD{{
na Yes
CABG, Coronary artery bypass graft; BARI, Bypass Angioplasty Revascularization Investigation; CAD, coronary artery disease; CABRI, Coronary Angioplasty versus Bypass
Revascularisation Investigation; na, not available; EAST, Emory Angioplasty versus Surgery Trial; ERACI I, Argentine Randomized Trial of Percutaneous Transluminal Coronary
Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease; GABI, German Angioplasty Bypass Surgery Investigation; LAD, left anterior descending coronary
artery; MASS, Medicine, Angioplasty, or Surgery Study; RITA, Randomised Intervention Treatment of Angina; AMIST, Angioplasty versus Minimally Invasive Surgery Trial;
ARTS, Arterial Revascularization Therapies Study; ERACI II, Argentine Randomized Trial of Coronary Angioplasty With Stenting Versus Coronary Bypass Surgery in Patients
withMultiple Vessel Disease; SIMA, Stenting versus InternalMammary Artery grafting trial; SoS, Stent or Surgery Trial;CARDia, Coronary Artery Revascularization inDiabetes;
FREEDOM, Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease; PRECOMBAT, Premier of Randomized Com-
parison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; SYNTAX, Synergy Between Percutaneous Cor-
onary InterventionWith Taxus and Cardiac Surgery; LMCA, left main coronary artery. yNot reported, assumed to be 0%. z3% of patients randomized to PCI were treated with a
bare metal stents. x2% of patients randomized to PCI were treated with angioplasty. k13% of patients randomized to PCI were treated with angioplasty. {30% of patients ran-
domized to PCI were treated with angioplasty. #35% of patients randomized to PCI were treated with drug-eluting stents. **28% of patients randomized to PCI were treated with
angioplasty. yyMain stem or main stem equivalent lesions. Main-stem-equivalent lesions were defined as a leading proximal LAD stenosis or stenosis of an LAD bypass (75%)
with a concomitantly documented proximal occlusion of the right coronary artery and/or the left circumflex artery. zz22% of lesions of patients randomized to PCI were treated
with angioplasty. xxDrug-eluting stents used in 69% of patients randomized to PCI and bare metal stents in 31% of patients. kkBare metal stents used in 5% of patients ran-
domized to PCI. {{Either multivessel disease including the left anterior descending coronary artery or isolated proximal left anterior descending coronary artery disease.
Acquired Cardiovascular Disease: Coronary Smit et al




TABLE 2. Meta-analyzed ORs for outcomes at the latest available follow-up and per era, PCI versus CABG
Outcome OR (95% CI) P value n I2 (95% CI),% P value heterogeneity
Mortality 1.1 (1.0-1.3) .05 31 21.4 (0-50) .15
Pre-stent era 1.2 (1.0-1.3) .06 9 0 (0-65) .48
Bare metal stent era 1.0 (0.8-1.3) .95 14 12.5 (0-51) .32
Drug-eluting stent era 1.2 (0.9-1.7) .21 8 43.8 (0-75) .09
Myocardial infarction 1.2 (0.9-1.5) .28 28 59.1 (38-73) <.01
Pre-stent era 1.2 (0.8-1.8) .43 7 49.8 (0-79) .06
Bare metal stent era 0.9 (0.6-1.4) .78 13 29.9 (0-64) .15
Drug-eluting stent era 1.4 (0.9-2.4) .18 8 65.0 (25-84) <.01
Repeat revascularization 4.5 (3.5-5.8) <.01* 31 78.3 (70-84) <.01
Pre-stent era 7.0 (5.1-9.7) <.01 9 69.6 (39-85) <.01
Bare metal stent era 4.5 (3.6-5.5) <.01 14 11.1 (0-49) .33
Drug-eluting stent era 2.5 (1.8-3.4) <.01 8 47.1 (0-76) .07
Stroke 0.7 (0.5-0.9) .01 12 0 (0-58) .67
Pre-stent era 1.0 (0.1-15.8) .98 1 0y 1.00
Bare metal stent era 0.9 (0.6-1.4) .59 5 0 (0-79) .42
Drug-eluting stent era 0.6 (0.4-0.8) <.01 6 0 (0-75) .84
Cardiac mortality 1.2 (0.9-1.6) .13 15 27.3 (0-61) .16
Pre-stent era 1.2 (0.9-1.5) .18 6 0 (0-75) .81
Bare metal stent era 1.1 (0.7-1.7) .82 6 35.0 (0-74) .17
Drug-eluting stent era 1.3 (0.6-3.2) .50 3 63.7 (0-90) .06
Angina-free survival 0.7 (0.6-0.9) .01 16 60.9 (33-77) <.01
Pre-stent era 0.7 (0.6-0.9) <.01 4 8.2 (0-86) .35
Bare metal stent era 0.7 (0.5-1.0) .03 10 68.9 (40-84) <.01
Drug-eluting stent era 1.2 (0.8-1.7) .40 2 0y .47
OR, Odds ratio; CI, confidence interval; n, number of studies included in the analysis. *<.00000001. y95% CI for I2 cannot be calculated for a meta-analysis of 1 or 2 studies.
Smit et al Acquired Cardiovascular Disease: Coronary
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D0.5 to 13 years (median, 5 years) with a median loss to
follow-up of 0.5% (range, 0%-8.0%). Arterial conduits
were used ranging from 37% to 100% of all grafts. Thirteen
trials exclusively used on-pump operating techniques; 9 tri-
als exclusively used off-pump operating techniques; and 8
trials used a mix of on- and off-pump operating techniques,
with a median of 18.8% (range, 3%-64%) off-pump use
across these trials. For 1 trial, information on the operating
technique was not available.
Trial Quality
All trials randomized patients; 12 out of 31 trials
specificallymentioned the use of computer-generated random
numbers or random number tables. The other 19 trials did not
mention the sequence-generation method. Fourteen out of 31
trials reported adequate procedures to conceal allocation.
Twenty-nine out of 31 studies had few exclusions after
randomization, whereas none of the trials was triple blind
(with blinding of participants, health care providers, and
outcome assessors). In 9 of the 31 trials, the outcome assessors
were blinded; in 22 of the 31 trials, no blinding at all occurred.
Trial quality is presented in detail in a table in Appendix E1.
Meta-Analysis of Outcomes Across All 31 Selected
Trials, per Era and per Time Period of Follow-up
Table 2 gives an overview of the outcomes at the latest
available follow-up (forest plots are shown in Appendix
E1). The odds for mortality were higher for PCI comparedThe Journal of Thoracic and Cato CABG across all studies (OR, 1.1; 95% CI, 1.0-1.3;
P ¼ .05), but not in each era separately. The odds for
myocardial infarction did not differ significantly (OR, 1.2;
95% CI, 0.9-1.5; P ¼ .28) across all studies and eras, nor
in each era separately. Repeat revascularization was more
common across all eras (OR, 4.5; 95% CI, 3.5-5.8;
P<.01) and in each era separately. The large heterogeneity
across all eras (I2¼ 78.3%) was due to a decline in the ORs
for repeat revascularization, with progressively less
difference in ORs from the pre-stent era to the
drug-eluting stent era (in meta-regression, there was
interaction between the year of the study’s start and the
OR for repeat revascularization (coefficient, 0.06 (95%
CI, 0.08 to 0.03; P< .01). The odds for stroke were
lower after PCI compared to CABG across all eras (OR,
0.7; 95% CI, 0.5-0.9; P¼ .01) and in the drug-eluting stent
era (OR, 0.6; 95% CI, 0.4-0.8; P<.01), but not in the bare
metal stent era (only 1 trial provided data on the outcome
stroke in the pre-stent era). Cardiac mortality was as
common after PCI across all eras (OR, 1.2; 95% CI,
0.9-1.6; P ¼ .13). Angina-free survival was less common
after PCI (OR, 0.7; 95% CI, 0.6-0.9; P ¼ .01) across all
eras and in the pre-stent and stent eras, but not in the
drug-eluting stent era.
We found no evidence of publication bias for the main
outcomes across all studies, neither on visual inspection
nor by using Duval and Tweedie’s trim and fill test.
Sensitivity analyses did not give evidence of a differentialrdiovascular Surgery c Volume 149, Number 3 835
TABLE 3. Meta-analyzed ORs for outcomes in patients with different types of vessel disease at the latest available follow-up across all eras, PCI
versus CABG
Outcome OR (95% CI) P value n I2 (95% CI),% P value heterogeneity
Mortality
Multivessel disease 1.2 (1.0-1.4) .02 12 18.3 (0-58) .26
Proximal LAD stenosis 1.0 (0.7-1.6) .95 11 0 (0-60) .61
Main stem stenosis 0.8 (0.5-1.2) .27 4 0 (0-85) .99
Myocardial infarction
Multivessel disease 1.1 (0.8-1.6) .6 10 71.2 (45-85) <.01
Proximal LAD stenosis 1.2 (0.6-2.4) .55 10 35 (0-69) .13
Main stem stenosis 1.4 (0.5-3.7) .48 4 0 (0-85) .58
Repeat revascularization
Multivessel disease 5.6 (4.2-7.4) <.01 12 77.3 (61-87) <.01
Proximal LAD stenosis 5.7 (3.5-9.1) <.01 11 10.1 (0-50) .39
Main stem stenosis 2.8 (1.7-4.5) <.01 4 0 (0-85) .63
Stroke
Multivessel disease 0.6 (0.4-1.1) .11 4 46.9 (0-82) .13
Proximal LAD stenosis 1.2 (0.2-6.9) .83 3 0 (0-90) .47
Main stem stenosis 0.4 (0.1-1.8) .23 3 0 (0-90) .87
OR, Odds ratio; CI, confidence interval; n, number of studies included in the analysis; LAD, left anterior descending coronary artery.
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Deffect in studies with different quality scores in the domains
of randomization, concealment, and blinding, nor was there
a differential effect when studies in which 10% or more of
patients were treated with a different type of PCI were
excluded (data not shown).
In the analyses of the main outcomes at different time
points of follow-up, at 5 years of follow-up, significantly
fewer patients died after CABG, compared to PCI (OR,
1.3; 95% CI, 1.1-1.5; P<.01) (see Appendix E1 for fig-
ures of the primary outcomes meta-analyzed at 0.5, 1, 1.5-
2, 2.5-3, 4, and 5 years). At 1 to 4 years of follow-up, the
ORs for death were hovering around 1; at 6 months, the
OR for death was 0.6 (95% CI, 0.2-1.7; P ¼ .31). After
4 and 5 years of follow-up, significantly fewer CABG pa-
tients got a myocardial infarction, compared to PCI pa-
tients (OR, 2.4; 95% CI, 1.6-3.6; P< .01; and OR, 1.6;
95% CI, 1.1-2.3; P ¼ .01, respectively). At each time
point of follow-up, there were significantly fewer repeat
revascularizations after CABG (P  .01 at each time
TABLE 4. Meta-analyzed ORs for outcomes in patients with on- and off-pu
drug-eluting stent eras, PCI versus CABG
Outcome OR (95% CI) P value
Mortality
On-pump surgery 0.9 (0.7-1.2) .40
Off-pump surgery 0.8 (0.5-1.3) .34
Myocardial infarction
On-pump surgery 1.0 (0.6-1.9) .94
Off-pump surgery 0.8 (0.4-1.6) .13
Repeat revascularization
On-pump surgery 5.3 (3.8-7.3) <.01
Off-pump surgery 3.2 (2.2-4.7) <.01
Stroke
On-pump surgery 0.8 (0.5-1.4) .54
Off-pump surgery 1.4 (0.1-20.6) .82
OR, Odds ratio; CI, confidence interval; n, number of studies included in the analysis. *9
836 The Journal of Thoracic and Cardiovascular Surgpoint). At a time period of 1-year follow-up, stroke was
significantly less frequent in the PCI group (OR, 0.5;
95% CI, 0.3-0.7; P<.01) but not at the other time periods
of follow-up.
Outcomes in Patients With Different Types of
Diseased Vessels
Twelve trials evaluated patients with multivessel disease,
11 trials analyzed patients with proximal LAD stenosis and
4 trials analyzed patients with left main stenosis (Table 3).
All-cause death was higher after PCI compared to surgery
in multivessel disease (OR, 1.2; 95% CI, 1.0-1.4;
P ¼ .02), but not in proximal LAD stenosis or left main
stenosis. Myocardial infarction did not occur significantly
more often after PCI compared to CABG in patients with
multivessel disease, proximal LAD stenosis, or left main
stenosis. Repeat revascularization favored CABG in
multivessel disease, proximal LAD stenosis, and main
stem stenosis patients. The OR for repeat revascularizationmp surgery at the latest available follow-up, in the bare metal stent and
n I2 (95% CI),% P value heterogeneity
4 0 (0-85) .50
9 0 (0-65) .52
4 58.8 (0-86) .06
8 18.9 (0-62) .28
4 26.4 (0-72) .25
9 0 (0-65) .67
3 10.8 (0-91) .33
2 32.8* .22
5% CI for I2 cannot be calculated for a meta-analysis of 1 or 2 studies.
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TABLE 5. Meta-analyzed ORs for outcomes in diabetes patients at the latest available follow-up across all eras, PCI versus CABG
Outcome OR (95% CI) P value n I2 (95% CI),% P value heterogeneity
Mortality 1.6 (1.2-2.1) <.01 12 27.4 (0-63) .18
Pre-stent era 1.5 (0.8-2.8) .26 4 49.6 (0-83) .11
Bare metal stent era 1.6 (1.0-2.5) .07 4 0.3 (0-85) .39
Drug-eluting stent era 1.7 (1.1-2.6) .02 4 51.6 (0-84) .10
Myocardial infarction 1.2 (0.8-2.0) .33 7 64.4 (20-84) .01
Pre-stent era 1.1 (0.6-1.9) .75 1 0* 1.00
Bare metal stent era 1.0 (0.3-2.7) .93 2 44.5* .18
Drug-eluting stent era 1.4 (0.7-2.6) .34 4 74.0 (28-91) <.01
Repeat revascularization 3.4 (2.1-5.7) <.01 6 72.0 (35-88) <.01
Pre-stent era — — 0 — —
Bare metal stent era 6.3 (3.3-11.8) <.01 2 0* .89
Drug-eluting stent era 2.7 (1.5-4.9) <.01 4 67.0 (0-90) <.01
Stroke 0.5 (0.3-0.8) .01 4 0 (0-85) .60
Pre-stent era — — 0 — —
Bare metal stent era — — 0 — —
Drug-eluting stent era 0.5 (0.3-0.8) .01 4 0 (0-85) .60
OR, Odds ratio; CI, confidence interval; n, number of studies included in the analysis. *95% CI for I2 cannot be calculated for a meta-analysis of 1 or 2 studies.
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Dwas around twice as high for multivessel disease (OR, 5.6;
95% CI, 4.2-7.4) and proximal LAD stenosis patients (OR,
5.7; 95% CI, 3.5-9.1), compared to patients with main stem
stenosis (OR, 2.8; 95% CI, 1.7-4.5). Differences in stroke
rate were not significant in either patient group.
Outcomes in Off-Pump Versus On-Pump Surgery
We excluded all trials from the pre-stent era, as in none of
these studies off-pump surgery was used. In the bare metal
stent and drug-eluting stent eras, 4 trials used on-pump
surgery exclusively, whereas 9 trials used off-pump surgery
exclusively. There was no significant difference between
CABG and PCI in mortality, myocardial infarction, and
stroke when off-pump surgery was used, or even when
on-pump surgery was used (Table 4). The meta-analyzed
primary outcomes did not differ between off-pump and
on-pump surgery. Only 2 (Drenth and Kim) out of 9 trials
that used off-pump surgery exclusively reported on stroke
as an outcome. Stroke was not more common after CABG
in these 2 studies (OR, 1.4; 95% CI, 0.1-20.6; P ¼ .82).
Outcomes in (Subgroups of) Patients With Diabetes
Twelve trials provided data on patients with diabetes
separately, usually as a subgroup except for the CARDia,
Future REvascularization Evaluation in patients with
Diabetes mellitus: Optimal management of Multivessel
disease (FREEDOM), and Veterans Affairs trials that
included patients with diabetes exclusively. The OR for
death favored CABG at the latest available follow-up across
all 12 studies (OR, 1.6; 95% CI, 1.2-2.1; P<.01), as well as
in the drug-eluting stent era (OR, 1.7; 95% CI, 1.1-2.6,
P ¼ .01) (Table 5). Myocardial infarctions did not differ
significantly. Repeat revascularization in patients with
diabetes occurred more frequently after PCI compared to
CABG (OR, 3.4; 95% CI, 2.1-5.7; P<.01). Data on strokeThe Journal of Thoracic and Cain patients with diabetes were only available for the
drug-eluting stent era and occurred less frequently after
PCI (OR, 0.5; 95% CI, 0.3-0.8; P ¼ .01). Effect sizes
were similar—though differences were not always
statistically significant—if only randomized data on
patients with diabetes were meta-analyzed (ie, subgroup
data were left out of the meta-analysis) with an OR for death
of 1.8 (95%CI, 0.8-3.8; P¼ .14); myocardial infarction 1.2
(95% CI, 0.5-3.0; P ¼ .65); repeat revascularization 2.6
(95% CI, 1.0-6.4; P ¼ .05); and stroke 0.5 (95% CI, 0.3-
0.8; P ¼ .01). In patients without diabetes (data from
subgroups only), there was no difference in mortality
(OR, 1.0; 95% CI, 0.9-1.2; P ¼ .74) or myocardial
infarction (OR, 1.0; 95% CI, 0.7-1.5; P¼ .95). Only 8 trials
provided data on subgroups of patients without diabetes. All
these 8 trials were from the pre-stent era (5 trials) or the
bare metal stent era (3 trials). Only 2 of them provided
data on repeat revascularization; therefore, we did not
meta-analyze repeat revascularization for patients without
diabetes, and none of them provided stroke data.DISCUSSION
To our knowledge, this meta-analysis is the most
up-to-date and complete overview of the effectiveness of
PCI versus CABG as revascularization strategies for
patients with coronary artery disease. This meta-analysis
includes 31 trials with 15,004 patients. Our main findings
are that CABG led to a small survival benefit over PCI.
This survival difference benefits patients with multivessel
disease and patients with diabetes, respectively. In addition,
repeat revascularization was less common after CABG,
though PCI is narrowing the gap over time. Stroke was
more common after CABG.
Composite endpoints of major adverse cardiac and
cerebrovascular events were not used. First, compositerdiovascular Surgery c Volume 149, Number 3 837
Acquired Cardiovascular Disease: Coronary Smit et al
A
C
Dendpoints are not uniformly defined across trials, which
leads to loss of information if only a subset of composite
endpoints can be meta-analyzed. Second, when included
in a composite endpoint, repeat revascularization dominates
the other composites as they occur at a much higher rate.
Third, there is now evidence that from a patient’s
perspective the components of composite endpoints are
not equally important. Patients found the risk of death to
be the most important outcome (relative weight 0.23),
followed by stroke (0.18), potential increased longevity
and recovery time (each 0.17), myocardial infarction
(0.14), and risk of repeat revascularization (0.11).E119
Our study is limited by the fact that we did not have access
to individual patient data, and analyzed patients at group
level. It is more difficult to unravel the complex
interactions of different patient-related factors (type of PCI
orCABG, type of vessel involvement, time of follow-up, sub-
groups involved) that influence outcomes, when less detailed
information is available. Therefore, results should be inter-
pretedwith caution. For example, that we found a (nonsignif-
icant) highermyocardial infarction rate after PCI in the drug-
eluting stent eramay be confounded by diabetes, as 3 of the 8
trials in the drug-eluting stent era were in patients with dia-
betes exclusively. In addition, subgroup analyses may have
been underpowered; many trials did not provide data on sub-
groups of interest. Subgroup analysesmay best be seen as hy-
pothesis generating as patients were usually not randomized
according to the subgroups of interest. As an example, the
difference in mortality between PCI and CABG is not
apparent when studies that used off-pump or on-pump
CABG exclusively were analyzed separately. In addition,
we tested a lot of hypotheses, which makes the chance of a
spurious finding higher. As a remedy, a stricter cut-off for sta-
tistical significance (eg, 0.01)might be used. If we had used a
cut-off of 0.01 the higher all-cause death after PCI compared
to surgery in multivessel disease would be nonsignificant.
Another limitation is that only few studies (12 of 31 trials)
provided data on stroke. Notably, only 2 of 9 trials that used
off-pump surgery exclusively provided stroke data. As the
risk of stroke is lower after off-pump CABG, compared to
on-pump CABG,E120 the difference in stroke risk in our
meta-analysis may have been overestimated in favor of PCI.
Heterogeneous definitions of myocardial infarction and
stroke further complicate the interpretation of our findings.
Because we did not perform a survival analysis, the
meta-analyzed ORs for myocardial infarction and repeat
revascularization might be overestimated. We did not
estimate the numbers at risk for each time point of follow-
up or a time-to event analysis. If we wanted to meta-
analyze hazard ratios, wewould have to leave out several tri-
als for each outcome, as not all trials performed time-to-event
analyses. For example, of the 7 trials with a follow-up of 8
years or longer, 4 trials had information missing that was
needed to calculate hazard ratios for some outcomes,838 The Journal of Thoracic and Cardiovascular Surgincluding 2 trials where such information was missing for
the outcome death. However, because the number of deaths
was small, especially in those studies with a follow-up of
<5 years, and because the loss to follow-upwas small at ame-
dian of 0.5%, we feel that the method used is sound.
The generalizability of our findings is limited by the fact
that only a very small proportion (median, 7.8%) of screened
patients were randomized. Exclusion criteria were usually
very strict; for example, patients with a recent myocardial
infarction, a low left ventricular ejection fraction, or a prior
PCI/CABGprocedure could not participate. The range of pa-
tients that is included in the RCTs is also limited because pa-
tients have to be eligible for both PCI andCABG. In real life,
many patients with coronary artery disease will not be
eligible for both procedures as, for example, PCI is not tech-
nically feasible or because they have contraindications for
CABG. Fortunately, the most recent trials included a much
higher proportion of screened patients, with trials on drug-
eluting stents including a median of 41% of screened pa-
tients (range, 3%-61%).
The Synergy Between Percutaneous Coronary Interven-
tion With Taxus and Cardiac Surgery (SYNTAX) score
has the potential to further refine the optimal treatment
strategy for individual patients. Today, knowledge on the
best treatment strategy in view of individual SYNTAX
scores stems from the SYNTAX study only, and needs to
be further elucidated. The ongoing EXCEL trial is designed
to further evaluate one of the outstanding questions the
SYNTAX trial raised: Do patients with left main disease
and a SYNTAX score 32 benefit more from PCI than
from CABG?CONCLUSIONS
Compared with PCI, CABG had a lower risk of death or
repeat revascularization but a higher risk of stroke. The
smaller risk of death favors patients with multivessel
disease or with diabetes.
Our findings are valid in settings and in patients
comparable to those of the original PCI versus CABG tri-
als: high-volume, state-of-the-art cardiac centers where
patient treatment is discussed and decided upon by a
team of interventional cardiologists and cardiac surgeons,
and in highly selective patients eligible for either interven-
tion. The results do not necessarily apply to other settings
or patients.
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FIGURE E1. Flow diagram of the search and selection process. RCT, Randomized controlled trial.
APPENDIX E1
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FIGURE E2. Meta-analyzed odds ratios for death after PCI or CABG at the latest available follow-up. PCI, Percutaneous coronary intervention; CABG,
coronary artery bypass grafting; CI, confidence interval; AMIST, Angioplasty versus Minimally Invasive Surgery Trial; ARTS, Arterial Revascularization
Therapies Study; BARI, Bypass Angioplasty Revascularization Investigation;CABRI, Coronary Angioplasty versus Bypass Revascularisation Investigation;
EAST, Emory Angioplasty versus Surgery Trial; ERACI I, Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus
Coronary Artery Bypass Surgery in Multivessel Disease; GABI, German Angioplasty Bypass Surgery Investigation; MASS, Medicine, Angioplasty, or
Surgery Study;RITA, Randomised Intervention Treatment of Angina;ERACI II, Argentine Randomized Trial of Coronary AngioplastyWith StentingVersus
Coronary Bypass Surgery in Patients with Multiple Vessel Disease; SIMA, Stenting versus Internal Mammary Artery grafting trial; SoS, Stent or Surgery
Trial; CARDia, Coronary Artery Revascularization in Diabetes; FREEDOM, Future REvascularization Evaluation in patients with Diabetes mellitus:
Optimal management of Multivessel disease; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus
and Cardiac Surgery.
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FIGURE E3. Meta-analyzed odds ratios for myocardial infarction after PCI or CABG at the latest available follow-up. PCI, Percutaneous coronary
intervention; CABG, coronary artery bypass grafting; CI, confidence interval; MI, myocardial infarction; AMIST, Angioplasty versus Minimally Invasive
Surgery Trial; ARTS, Arterial Revascularization Therapies Study; CABRI, Coronary Angioplasty versus Bypass Revascularisation Investigation; EAST,
Emory Angioplasty versus Surgery Trial; ERACI I, Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary
Artery Bypass Surgery in Multivessel Disease;GABI, German Angioplasty Bypass Surgery Investigation;MASS, Medicine, Angioplasty, or Surgery Study;
RITA, Randomised Intervention Treatment of Angina; ERACI II, Argentine Randomized Trial of Coronary Angioplasty With Stenting Versus Coronary
Bypass Surgery in Patients with Multiple Vessel Disease; SIMA, Stenting versus Internal Mammary Artery grafting trial; SoS, Stent or Surgery Trial;
CARDia, Coronary Artery Revascularization in Diabetes; FREEDOM, Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal
management of Multivessel disease; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-
Eluting Stent in Patients with Left Main Coronary Artery Disease; SYNTAX, Synergy Between Percutaneous Coronary InterventionWith Taxus and Cardiac
Surgery.
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FIGURE E4. Meta-analyzed odds ratios for repeat revascularization after PCI or CABG at the latest available follow-up. PCI, Percutaneous coronary
intervention; CABG, coronary artery bypass grafting; CI, confidence interval; RR, repeat revascularization; TVR, target vessel revascularization; AMIST,
Angioplasty versus Minimally Invasive Surgery Trial; ARTS, Arterial Revascularization Therapies Study; BARI, Bypass Angioplasty Revascularization
Investigation; CABRI, Coronary Angioplasty versus Bypass Revascularisation Investigation; EAST, Emory Angioplasty versus Surgery Trial; ERACI I,
Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease;
GABI, German Angioplasty Bypass Surgery Investigation; MASS, Medicine, Angioplasty, or Surgery Study; RITA, Randomised Intervention Treatment
of Angina;ERACI II, Argentine Randomized Trial of Coronary AngioplastyWith Stenting Versus Coronary Bypass Surgery in Patients withMultiple Vessel
Disease; SIMA, Stenting versus Internal Mammary Artery grafting trial; SoS, Stent or Surgery Trial; CARDia, Coronary Artery Revascularization in
Diabetes;FREEDOM, Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management ofMultivessel disease; PRECOMBAT,
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery
Disease; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
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FIGURE E5. Meta-analyzed odds ratios for stroke after PCI or CABG at the latest available follow-up. PCI, Percutaneous coronary intervention; CABG,
coronary artery bypass grafting; CI, confidence interval; ARTS, Arterial Revascularization Therapies Study;CARDia, Coronary Artery Revascularization in
Diabetes; FREEDOM, Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease; MASS,
Medicine, Angioplasty, or Surgery Study; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus
and Cardiac Surgery.
FIGURE E6. Meta-analyzed odds ratios for cardiac death after PCI or CABG at the latest available follow-up. PCI, Percutaneous coronary intervention;
CABG, coronary artery bypass grafting; CI, confidence interval; BARI, Bypass Angioplasty Revascularization Investigation; ERACI I, Argentine
Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease; ERACI II,
Argentine Randomized Trial of Coronary Angioplasty With Stenting Versus Coronary Bypass Surgery in Patients with Multiple Vessel Disease; MASS,
Medicine, Angioplasty, or Surgery Study; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; RITA, Randomised Intervention Treatment of Angina; SIMA, Stenting versus
Internal Mammary Artery grafting trial; SoS, Stent or Surgery Trial; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and
Cardiac Surgery.
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FIGURE E7. Meta-analyzed odds ratios for angina-free survival after PCI or CABG at the latest available follow-up. PCI, Percutaneous coronary
intervention; CABG, coronary artery bypass grafting; AFS, angina-free survival; CI, confidence interval; AMIST, Angioplasty versus Minimally Invasive
Surgery Trial; ARTS, Arterial Revascularization Therapies Study; CABRI, Coronary Angioplasty versus Bypass Revascularisation Investigation;
ERACI I, Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery inMultivessel Disease;
ERACI II, Argentine Randomized Trial of Coronary Angioplasty With Stenting Versus Coronary Bypass Surgery in Patients with Multiple Vessel Disease;
FREEDOM, Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease; GABI, German
Angioplasty Bypass Surgery Investigation; MASS, Medicine, Angioplasty, or Surgery Study; SoS, Stent or Surgery Trial.
FIGURE E8. Meta-analyzed odds ratios for death per time period of follow-up, PCI versus CABG. OR, Odds ratio; n, number of studies meta-analyzed;
y, years of follow-up.
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FIGURE E9. Meta-analyzed odds ratios for myocardial infarction per time period of follow-up, PCI versus CABG. OR, Odds ratio; n, number of studies
meta-analyzed; y, years of follow-up.
FIGUREE10. Meta-analyzed odds ratios for repeat revascularization per time period of follow-up, PCI versus CABG.OR, Odds ratio; n, number of studies
meta-analyzed; y, years of follow-up.
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FIGURE E11. Meta-analyzed odds ratios for stroke per time period of follow-up, PCI versus CABG.OR, Odds ratio; n, number of studies meta-analyzed;
y, years of follow-up.
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AMIST A A A C
ARTS A A A C
BARI A A A C
Boudriot A A A B
CABRI A A A C
CARDia A A A B
Cisowski et al B B A B
Diegeler et al A A A C
Drenth et al B B A C
EAST B B A B
ERACI I B B A C
ERACI II A A A C




B B A C
GABI B B A C
Goy et al B B A C
Grip et al B B A C
Hong et al B B A C
Kim et al B B A C
Le Mans B B A C
MASS I B B A C
MASS II B B A C
Myoprotect B B A C
Octostent A A A B
PRECOMBAT A B A B
RITA A A A B
SIMA B B A C
SoS A A A C
SYNTAX B A B B
Thiele B B A C
Veterans Affairs B A B B
AMIST, Angioplasty versus Minimally Invasive Surgery Trial; ARTS, Arterial
Revascularization Therapies Study; BARI, Bypass Angioplasty Revascularization
Investigation; CABRI, Coronary Angioplasty versus Bypass Revascularisation
Investigation; CARDia, Coronary Artery Revascularization in Diabetes; EAST,
Emory Angioplasty versus Surgery Trial; ERACI I, Argentine Randomized Trial of
Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass
Surgery in Multivessel Disease; ERACI II, Argentine Randomized Trial of Coronary
AngioplastyWith Stenting Versus Coronary Bypass Surgery in Patients withMultiple
Vessel Disease; FREEDOM, Future REvascularization Evaluation in patients with
Diabetes mellitus: Optimal management of Multivessel disease; GABI, German
Angioplasty Bypass Surgery Investigation;MASS, Medicine, Angioplasty, or Surgery
Study; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus
Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary
Artery Disease; RITA, Randomised Intervention Treatment of Angina; SIMA,
Stenting versus Internal Mammary Artery grafting trial; SoS, Stent or Surgery Trial;
SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and
Cardiac Surgery. *Adequacy of the randomization process: A, adequate sequence
generation is reported (such as computer-generated random numbers or random
number tables); B, did not specify one of the adequate reported methods in (A) but
mentioned randomization method; C, other methods of allocation that appear to be
unbiased; D, did not specify one of the adequate reported methods in (A) but
mentioned randomization method. yAdequacy of the allocation concealment process:
A, adequate measures to conceal allocations. Concealment will be deemed adequate
where randomization is centralized or pharmacy controlled, or where the following
are used: serially numbered containers, on-site computer-based systems where
assignment is unreadable until after allocation, other methods with robust
methods to prevent foreknowledge of the allocation sequence to clinicians and
patients; B, unclear concealed trials, in which the authors either did not report
allocation concealment approach at all or reported an approach that did not fall
into one of the categories in (A); C, inadequately concealed trials, in which
method of allocation is not concealed. Inadequate approaches will include the
use of alternation, case record numbers, days of the week, open random number
lists, and serially numbered envelopes, even opaque. zPotential for selection bias
after allocation: A, studies where an intention to treat analysis is possible and few
exclusions (with adequate reporting of these exclusions); B, studies that reported
exclusions as reported in (A), but exclusions were less than 10%; C, no reporting
of exclusions; exclusions of 10% or more or wide differences in exclusions
between groups. xAdequacy of masking: A, double (or triple) blind; B,
single-blind; C, nonblind; D, unclear.
=
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